These bispecific molecules that antagonize GIPR and agonize GLP-1R pathways led to decreases in BW and improvements in metabolic parameters in obese mice and monkeys 34
MT-1 (Melanotan I, Afamelanotide, CAS 75921-69-6) is a synthetic linear tridecapeptide analog of -MSH with two targeted modifications Nle and D-Phe that enhance metabolic stability
If you're adequate but on the lower end of normal, optimizing your levels may produce a subtle, gradual benefit
According to the data, it has the following pharmacokinetics: Time to max concentration: 24-72 hours Max availability: 89% Half life: approximately 7 days Time to steady state of current dose: 4-5 weeks With weekly dosing, the graph for Semaglutide is shown below
GLP-1 is the new statin, not the new bariatric surgery A trial called SURMOUNT-4 should change how every doctor talks about GLP-1 drugs like Ozempic and Mounjaro
Al-Aly and colleagues found a beneficial relationship between the continuous use of GLP-1s and fewer cardiovascular events
